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Abstract: Zolpidem modiﬁ  ed-release (MR) is the ﬁ  rst hypnotic agent to be marketed in an 
extended-release formulation. Zolpidem MR is a two-layered, biphasic release tablet indicated 
for the management of induction of sleep and sleep maintenance. The pharmacokinetics of the 
drug are similar to those of immediate-release zolpidem. Two double-blind, placebo-controlled, 
parallel-group trials demonstrated efﬁ  cacy in adults and elderly patients treated with zolpidem 
MR for 3 weeks without signiﬁ  cant impairment in next-day psychomotor functioning. The 
most common adverse effects with zolpidem MR were dizziness, somnolence, and headache. 
A starting dose of zolpidem MR 12.5 mg is recommended for adults and 6.25 mg for elderly 
patients.
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Introduction
Zolpidem, a non-benzodiazepine sedative/hypnotic, was marketed as the immediate-
release product in the US in 1993 and in Europe in 1988 for the short-term treatment 
of insomnia (Roth et al 2006). Zolpidem is effective in reducing the time to sleep onset 
and increasing total sleep time, however its effect on sleep maintenance has not been 
consistently demonstrated (Scharf et al 1994; Roth et al 1995). The hypnotic effects of 
zolpidem have been reported primarily in the ﬁ  rst 3 hours post-dose which can lead to 
subtherapeutic effects on sleep maintenance in the later portion of the night for some 
patients (Besset et al 1995).
In an effort to expand the coverage of sleep complaints and overcome the lack of 
efﬁ  cacy in sleep maintenance, the manufacturer (Sanoﬁ  -Aventis) developed a modiﬁ  ed-
release (MR) formulation of zolpidem tartrate that was approved for use in the US in 
2005. The coated, two-layer, zolpidem MR tablet is a biphasic release dosage form 
(Ambien CR Prescribing Information 2007). The ﬁ  rst layer immediately releases drug 
while the second layer is controlled-release. The tablet was designed to mimic initial 
dosing while the extended-release of drug maintains a plasma concentration for a longer 
duration of time than the immediate-release product (Weinling et al 2006).
Pharmacology
Zolpidem tartrate is an imidazopyridine, nonbenzodiazepine hypnotic that differs in 
chemical structure from benzodiazepines and other hypnotics. The proposed hypnotic 
mechanism of action is via modulation of the gamma amino butyric acid (GABA) 
chloride ion channel macromolecular complex (Ambien CR Prescribing Information 
2007). Zolpidem demonstrates preferential binding at the benzodiazepine type 1 recep-
tor (BZ1) on the α subunit of the GABAA receptor (Ambien CR prescribing information 
2007). Unlike benzodiazepines that bind non-selectively to activate all benzodiazepine 
receptor subtypes, zolpidem’s selectivity for the BZ1 receptor confers sedative activity 
without producing appreciable anticonvulsant, anxiolytic, and myorelaxant effects 
(Drover 2004; Ambien CR Prescribing Information 2007).Neuropsychiatric Disease and Treatment 2007:3(5) 522
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Pharmacokinetics
Two pharmacokinetic studies of zolpidem MR have been 
published. The pharmacokinetic proﬁ  les of zolpidem MR 
12.5 mg and the immediate-release zolpidem 10 mg were 
compared in a study of 24 men (Weinling et al 2006). The 
time to peak concentration (tmax) and elimination half-life 
for the modiﬁ  ed- and immediate-release formulations were 
similar; however zolpidem MR maintained peak plasma 
concentrations for a longer duration of time (3–6 hours post-
dose) in comparison with the immediate-release formulation 
(Weinling et al 2006). Greenblatt et al (2007) compared the 
pharmacokinetics and pharmacodynamics of single doses of 
immediate-release zolpidem 10 mg, zolpidem MR 10 mg, and 
placebo in 81 healthy volunteers in a 3-way crossover trial. 
The tmax of zolpidem MR (2.0 hours) was signiﬁ  cantly longer 
than immediate-release zolpidem (2.4 hours) (p < 0.004). 
After dose normalization, the maximum concentration (Cmax) 
for zolpidem MR was signiﬁ  cantly lower than the Cmax of 
immediate-release zolpidem (Greenblatt et al 2007).
Zolpidem MR is rapidly absorbed after oral administra-
tion and reaches a peak median concentration in 1.5 hours 
(range, 0.5–3.5 hours). The Cmax of zolpidem MR was 82% 
of the immediate-release product and the absolute bioavail-
ability was 68% (Weinling et al 2006). Administration of 
zolpidem MR with food decreased the peak concentration by 
30% and area under the plasma concentration curve (AUC) 
by 23%. The median tmax was prolonged from 2 to 4 hours 
with food and the product labeling indicates that ingestion 
with food may delay the hypnotic effects of zolpidem MR 
(Ambien CR prescribing information 2007).
Plasma protein binding of zolpidem is about 92.5%. It is 
primarily metabolized via cytochrome P450 3A4 isoenzymes 
to inactive metabolites. The major routes of metabolism 
include hydroxylation and oxidation (Salva and Costa 1995). 
Zolpidem MR has an average elimination half-life of 2.8 hours 
(range, 1.62–4.05 hours) (Ambien CR Prescribing Information 
2007). Accumulation was not observed in adult and elderly 
patients who received once a day dosing for a period of 
2 weeks (Ambien CR Prescribing Information 2007).
Special populations
The tmax and elimination half-life of 6.25 mg of zolpidem MR 
in the elderly was 2 and 2.9 hours, respectively. The safety 
and efﬁ  cacy of zolpidem MR has not been established in 
children less than 18 years of age (Ambien CR Prescribing 
Information 2007).
An evaluation of the pharmacokinetics of zolpidem MR 
in patients with hepatic or renal impairment has not been 
reported. The half-life of the immediate-release formulation 
of zolpidem was increased from 2.2 to 9.9 hours in patients 
with cirrhosis (Ambien CR Prescribing Information 2007). 
A reduction in the initial dosage of zolpidem MR is recom-
mended for patients with hepatic insufﬁ  ciency. The pharma-
cokinetics of immediate-release zolpidem in patients with 
renal impairment were not altered and dosage adjustments 
are not necessary in this patient population (Ambien CR 
Prescribing Information 2007).
Efﬁ  cacy trials
Roth et al (2006) conducted a worldwide, multicenter, 
double-blind, placebo-controlled, parallel-group study in 
212 adult outpatients, aged 18–64 years, with primary in-
somnia (diagnosed using Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition). The purpose of this study 
was to evaluate the efﬁ  cacy and safety of zolpidem MR 12.5 
mg. The duration of treatment was 21 days with 2 nights at 
the outset of the study and 2 nights at the end of the study 
consisting of single-blind placebo. The placebo substitution 
at the end of the trial was to determine the effect of discon-
tinuing drug. The patients received zolpidem MR 12.5 mg 
or placebo at bedtime for a total duration of 3 weeks. The 
efﬁ  cacy parameters were determined by polysomnography 
(PSG) in a sleep laboratory, speciﬁ  cally the latency to persis-
tent sleep (LPS), sleep efﬁ  ciency (SE), wake time after sleep 
onset (WASO), and number of awakenings (NA). Daytime 
subjective sleep estimates were derived from sleep question-
naires that were completed each morning and evening by 
study subjects. Evaluation with PSG for 8 hours occurred 
for 3 evaluation periods – on nights 1/2, 15/16, and 22/23. 
Within 30 minutes of awakening, subjects completed a bat-
tery of tests to assess daytime symptoms and psychomotor 
impairment (ie, morning sleep questionnaire, Digit Symbol 
Substitution Test [DSST], and Rey Auditory Verbal Learning 
Test [RAVLT]) (Roth et al 2006).
One hundred and ninety-two subjects completed the Roth 
et al study. Zolpidem MR signiﬁ  cantly reduced the LPS on 
nights 1/2 (p < 0.0001) and nights 15/16 (p < 0.0338) and 
increased SE on nights 1/ 2 (p < 0.0001) and nights 15/16 
(p < 0.0172) (Roth et al 2006). There was a signiﬁ  cant 
improvement in sleep maintenance through reduction in 
WASO during the initial 6 hours of sleep and in number 
of awakenings with zolpidem MR compared with placebo 
on nights 1/2 and 15/16 (p < 0.0001). After adjustment for 
baseline differences in the treatment groups patients in the 
zolpidem MR group were awake for an average of about 
34 minutes less over the ﬁ  rst 6 hours of sleep on nights 1/2 Neuropsychiatric Disease and Treatment 2007:3(5) 523
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and about 30 minutes less on nights 15/16 compared with 
placebo. There was no difference in next-morning psycho-
motor performance on the DSST and RAVLT between the 
zolpidem MR and placebo groups. Subjective reports of sleep 
improvement did not consistently support zolpidem-MR over 
placebo. Upon discontinuation of zolpidem MR there was 
a signiﬁ  cant worsening of LPS, WASO and SE (p < 0.05) 
compared with baseline only on the ﬁ  rst night. Somnolence, 
nausea and dizziness were reported more frequently in 
zolpidem MR-treated patients (Roth et al 2006).
A separate study reported in the product labeling 
describes results of a trial in 205 elderly outpatients with 
primary insomnia. This was a randomized, double-blind, 
placebo-controlled, parallel-group study evaluating zolpidem 
MR 6.25 mg for 3 weeks. A total of 198 subjects completed 
the study. Efﬁ  cacy was determined using PSG on nights 1/2 
and 15/16. Study participants completed sleep questionnaires 
daily. There was a signiﬁ  cant reduction in WASO in the zol-
pidem MR group compared with placebo as measured over 
the ﬁ  rst 6 hours of nights 1/2 and the ﬁ  rst 4 hours of nights 
15/16. Zolpidem MR decreased LPS during both evalua-
tion periods compared with placebo. Patient-rated global 
improvement in sleep indicated that zolpidem MR “was 
superior” to placebo during the ﬁ  rst two nights and on nights 
15/16 (Ambien CR Prescribing Information 2007).
The package labeling indicates that wakefulness 
measured by PSG was increased in the zolpidem MR group 
“at the end of the night” compared with placebo in both of 
these efﬁ  cacy trials (Ambien CR Prescribing Information 
2007).
Adverse effects
About 3.5% of patients discontinued zolpidem MR therapy 
secondary to an adverse event during clinical trials (n = 201). 
The most common reasons for discontinuation were somno-
lence (1%) and dizziness (1%). Similarly, trials in the US 
with zolpidem immediate-release (n = 1701) reported 4% of 
patients discontinued treatment secondary to an adverse drug 
reaction (eg, daytime drowsiness, dizziness, headache and 
nausea/vomiting; all < 1%) (Ambien Prescribing Information 
2005; Ambien CR Prescribing Information 2007).
The most frequently reported adverse effects in adults 
taking zolpidem MR were headache (19%), somnolence 
(15%), dizziness (12%), and nausea (7%). Comparable 
adverse effects were observed in elderly patients – headache 
(14%), somnolence (8%), and dizziness (6%); however 
nausea was infrequently reported. About 6% of elderly 
patients experienced nasopharangitis. Although headache 
was the most frequently reported adverse event in both adult 
and elderly populations the difference in incidence of this 
adverse effect in patients receiving zolpidem MR vs placebo 
was minimal (19% vs 16%, and 14% vs 11%, respectively) 
(Ambien CR Prescribing Information 2007).
Disorientation, visual disturbances, hallucinations, and 
balance disorders were reported more frequently in the pack-
age labeling with zolpidem MR than the immediate-release 
formulation (Ambien Prescribing Information 2005; Ambien 
CR Prescribing Information 2007). A summary of 20 case 
reports identiﬁ  ed visual, auditory, tactile and hypnogogic hal-
lucinations related to the use of zolpidem immediate-release 
(Toner et al 2000). It appears that hallucinations may be dose 
dependent and occur more frequently in women (80%) (Toner 
et al 2000). Elko et al (1998) reported that hallucinations may 
be related to concurrent antidepressant use (58.8%) and begin 
15–60 minutes after taking zolpidem immediate-release. 
The duration of hallucinations ranged from short (about 30 
minutes) or prolonged and last for up to 7 hours (Elko et al 
1998). Nocturnal sleep-related eating disorder was reported 
in a case series of 5 patients with zolpidem immediate-release 
doses of 5–30 mg nightly that resolved when the drug was 
discontinued (Morgenthaler and Silber 2002). The United 
States Food and Drug Administration (FDA) requested label-
ing changes on all sedative hypnotics to warn of complex 
sleep-related behaviors (eg, sleep driving, sleep-eating) and 
severe allergic reactions in March of 2007 (FDA 2007).
Residual effects
Medications used to treat insomnia can cause next-day 
residual effects and rebound insomnia. Five clinical stud-
ies (ie, 3 adult, 2 elderly) determined zolpidem MR did not 
have a signiﬁ  cant effect on vigilance, memory, or motor 
function eight hours post nighttime dose. However, a total 
of 15% of adult and 6% of elderly patients taking zolpidem 
MR reported next-day somnolence compared with 2% and 
5%, respectively, of those taking placebo. In two clinical 
studies, rebound insomnia was observed on the ﬁ  rst night 
after abrupt discontinuation of zolpidem MR in patients with 
primary insomnia. On the second night symptoms were not 
worse than those reported at baseline (Ambien CR Prescrib-
ing Information 2007).
Two published trials examined the residual psychomo-
tor and cognitive effects of zolpidem MR (Blin et al 2006; 
Hindmarch et al 2006). Blin et al compared the effects of a 
single-dose of zolpidem MR 12.5 mg and ﬂ  urazepam 30 mg 
(as the control drug) with placebo in 18 healthy, Cauca-
sian subjects in a double-blind, placebo-controlled, 3-way Neuropsychiatric Disease and Treatment 2007:3(5) 524
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crossover (Blin et al 2006). The subjects were between the 
ages of 18–40 years (mean 26.3 ± 4.6 years). The dosing was 
separated by at least a 21-day washout period and 5 neuro-
psychological tests were performed 8.5 hours after night-time 
dosing to assess psychomotor and cognitive effects. These 
tests included the critical ﬂ  icker fusion frequency (CFF), 
Hicks choice reaction time (CRT), immediate and delayed 
recall of supraspan word lists (iWR and dWR, respectively), 
compensatory tracking task (CTT), and DSST. Two ques-
tionnaires were used to evaluate subjective assessment of 
sleep – the Leeds sleep evaluation questionnaire (LSEQ) 
and the Bond and Lader visual analog scale (VAS). On the 
psychomotor and cognitive tests there was no signiﬁ  cant 
difference between zolpidem MR and placebo in changes 
on mean CFF, CRT, iWR, dWR, CTT deviation, or DSST. 
The mean response time on CRT was signiﬁ  cantly longer 
with zolpidem MR compared with placebo (p = 0.0105). 
Flurazepam treatment resulted in signiﬁ  cant changes in all 
measures except the DSST compared with placebo indicating 
residual effects of this benzodiazepine. Results on the subjec-
tive measures showed that both zolpidem MR and ﬂ  urazepam 
were effective in ease of falling asleep and the perceived 
quality of sleep on the LSEQ compared with placebo. Only 
ﬂ  urazepam scored signiﬁ  cantly lower on LSEQ measures 
of ease of awakening and behavior after awakening. On the 
Bond and Lader VAS, ﬂ  urazepam impaired alertness and 
both study drugs signiﬁ  cantly increased calmness compared 
with placebo. The limitations of this study were the small 
sample size, and reduced generalizability of results to patients 
with insomnia, elderly patients, and non-Caucasians.
Hindmarch et al reported results of a randomized, double-
blind, placebo-controlled, 4-way crossover trial in 24 healthy 
elderly subjects (mean age 70.7 ± 3.8 years). Each subject 
received zolpidem MR 6.25 mg, zolpidem MR 12.5 mg, 
placebo, and ﬂ  urazepam 15 mg (as the control drug). The 
psychometric tests performed were identical to those used in 
the Blin et al 2006 trial. The LSEQ was the only subjective 
assessment performed. Twenty-three subjects completed the 
trial. There was no signiﬁ  cant difference between both doses 
of zolpidem MR and placebo on psychomotor performance 
tests. There was a signiﬁ  cant difference in performance 
between ﬂ  urazepam and placebo on all tests, except DSST. 
On the subjective testing, both doses of zolpidem MR and 
ﬂ  urazepam demonstrated signiﬁ  cant improvements in ease 
of getting to sleep and the quality of sleep compared with 
placebo. Somnolence and dizziness were the most frequently 
reported adverse effects for all drug treatments. Elderly 
subjects administered 6.25 mg of zolpidem MR experienced 
adverse effects similar to adults ( 64 years of age) who 
received zolpidem MR 12.5 mg. The major limitation in this 
study was that it was conducted in healthy elderly subjects; 
the residual effects of zolpidem MR in patients with insomnia 
are not known (Hindmarch et al 2006).
A criticism of both the Blin et al and Hindmarch et al 
studies of residual effects of zolpidem MR is the selection of 
ﬂ  urazepam as the control drug. Flurazepam is a long-acting 
benzodiazepine with known daytime effects post-dose where 
a difference would be likely to have occurred (Kupfer and 
Reynolds 1997).
Rebound insomnia
Within two placebo-controlled studies assessing patients with 
primary insomnia, after abrupt discontinuation of zolpidem 
MR, rebound insomnia was reported the ﬁ  rst night. The 
second night, symptoms were no worse than those reported 
at baseline. (Roth et al 2006; Ambien CR Prescribing Infor-
mation 2007)
Drug interactions
Data on the drug interactions of zolpidem MR are based on 
studies performed with the immediate-release formulation. 
Zolpidem has additive effects on psychomotor performance 
when administered with alcohol or chlorpromazine and 
reduction of alertness with imipramine (Ambien CR Prescrib-
ing Information 2007). Additive depressant effects of zolpi-
dem are anticipated when it is combined with drugs known 
to depress the central nervous system. The benzodiazepine 
receptor antagonist ﬂ  umazenil reversed the hypnotic effect 
of zolpidem (Ambien CR Prescribing Information 2007).
Zolpidem co-administered with haloperidol, digoxin, 
warfarin, cimetidine, or ranitidine did not result in altered 
pharmacokinetics of either drug (Salva and Costa 1995; 
Ambien CR Prescribing Information 2007). Sertraline 50 mg 
was shown to signiﬁ  cantly increase the Cmax and decrease the 
tmax of zolpidem by 43% and 53%, respectively (Allard et al 
1999; Ambien CR Prescribing Information 2007).
Potential inhibitors and inducers of the CYP 3A4 pathway 
may affect zolpidem pharmacokinetics, although the clinical 
signiﬁ  cance of such alterations appears minimal. Ketocon-
azole impaired the DSST scores and recall scores, increased 
the area under the plasma concentration curve (AUC), and 
prolonged the elimination half-life of zolpidem immediate-
release (Greenblatt et al 1998). Coadministration of zolpidem 
with ﬂ  uconazole or itraconazole did not produce signiﬁ  cant 
changes in zolpidem pharmacokinetics or pharmacodynamics 
(Greenblatt et al 1998). Rifampin administered at 600 mg/day Neuropsychiatric Disease and Treatment 2007:3(5) 525
Zolpidem MR review
for 5 consecutive days reduced the AUC, Cmax, half-life, and 
pharmacodynamic effects of zolpidem (Villikka et al 1997; 
Ambien CR Prescribing Information 2007).
Dosing and administration
The generally recommended starting dose of zolpidem MR 
is 12.5 mg by mouth immediately before bedtime for the 
average adult patient. A lower dose of 6.25 mg is suggested 
for the elderly, and for patients with debilitations or hepatic 
insufﬁ  ciency (Ambien CR Prescribing Information 2007). 
Zolpidem MR is an extended-release tablet, therefore it 
should be swallowed whole, and not cut-in-half, divided, 
crushed or chewed. This drug should also be stored at tem-
peratures between 15 °C and 25 °C (59 °F–77 °F) (Ambien 
CR Prescribing Information 2007).
According to the manufacturer, persons taking zolpi-
dem MR should be warned against engaging in activities 
that require complete mental alertness or motor coordina-
tion (eg, operating machinery or driving a car) after taking 
zolpidem MR. Additionally, zolpidem MR should not be 
ingested with alcohol, and may cause additive effects when 
used with other CNS depressants (Ambien CR Prescribing 
Information 2007).
Economics of insomnia
Insomnia has a signiﬁ  cant negative economic impact that 
can be described in terms of direct and indirect costs. Direct 
costs, that include use of healthcare services and the cost of 
prescription and non-prescription sleep medications, have 
been estimated to be US$13.9 billion (Walsh and Englehardt 
1999). Expenditure on sleep medications was included in this 
ﬁ  gure and was estimated to be US$809.92 million (Walsh 
and Englehardt 1999; Martin et al 2004). Indirect burdens of 
insomnia reﬂ  ect a decrease in societal economic output and are 
attributable to absenteeism, loss of productivity, and accidents 
(Walsh 2004). The cost for these losses has been placed at 
nearly US$28 billion (National Sleep Foundation 2005). 
Insomnia was associated with medical complications and an 
increased risk for substance abuse (Stoller 1994; Leger et al 
2002). The estimated cost of insomnia-related depression was 
US$1 billion per year and the cost of alcohol abuse resulting 
from insomnia ranged from US$8.5 to US$11.6 billion per year 
(Stoller 1994; Martin et al 2004). An economic evaluation of 
zolpidem MR in insomnia has not been reported to date.
Summary
The place of zolpidem MR in therapy is unknown at this 
time. The fact that it is the ﬁ  rst extended-release hypnotic 
to be approved for sleep induction and maintenance makes 
it unique. There are no head-to-head clinical comparisons of 
the efﬁ  cacy of zolpidem immediate-release or other hypnotics 
(ie, temazepam, eszopiclone, zaleplon) with zolpidem MR. It 
is only speculative that it has a longer duration of effect than 
the immediate-release product or that it is similar in efﬁ  cacy 
to other hypnotics used in patients with sleep maintenance 
complaints. Pharmacokinetically, this formulation offers a 
longer duration of time in which the plasma concentration 
of zolpidem is elevated post-dose. Pharmacodynamically, 
zolpidem MR potentiates sleep maintenance for greater than 
3 hours and up to 6 hours compared with placebo in patients 
with primary insomnia (Roth et al 2006). Overall, zolpidem 
MR provides an additional pharmacotherapeutic option in 
patients whose sleep is not maintained by immediate-release 
zolpidem to provide a longer duration of sleep.
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